Evaluation of Pain and Inflammation After Injection of Lucentis vs Eylea for Treatment of Wet Macular Degeneration

Part of paid clinical trials in Reno, Nevada.

Sponsor
Arshad Khanani
Study ID
NCT01926977
Phase
PHASE1/PHASE2
Status
Completed

Conditions

  • Neovascular Age-Related Macular Degeneration

Eligibility Criteria

Sex
ALL
Age
65 Years - N/A
Healthy Volunteers
Accepted

Interventions

  • Ranibizumab 0.5mg — DRUG
    Patient will receive intravitreal injection of Ranibizumab 0.5mg.
  • Aflibercept 2.0mg — DRUG
    Patients will receive intravitreal injection of Aflibercept 2.0mg.

Study Details

This study is designed to compare the post injection inflammation and pain seen after intravitreal injections of Ranibizumab vs Aflibercept.

Key Dates

Start date
Sep 30, 2013
Status verified
Feb 2016
Primary completion
May 31, 2014
Completion
May 31, 2014

Study Design

Enrollment
100 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Active Comparator: Ranibizumab 0.5mg Intravitreal injection
    Intravitreal injection of Ranibizumab 0.5mg once
  • Active Comparator: Aflibercept 2.0mg Intravitreal injection
    Intravitreal Aflibercept 2.0mg once

Primary Outcome Measure

Evidence of Anterior Chamber Inflammation [ Time Frame: 24 to 48 hours (visit #1) and 5 to 7 days (visit #2) ]

Locations (1)

FacilityCityStateZIPSite coordinators
Sierra Eye AssociatesRenoNevada89502-

Find similar trials in Reno, NV

By research site
Sierra Eye Associates· Reno, NV

Related Studies